Medarex Inc.

Bristol-myers Squibb Compnay

Kyowa Hakko Kirin Co., Limited

E. R. Squibb Sons, Inc.

Genmab A+s

N.v. Organon

Kirin Brewery Company, Limited

Edward L Halk

Paul Parren

Alan J Korman

Nils Lonberg

Isao Ishida

Kazuma Tomizuka

Mark J Selby

Tibor P Keler

Maria N Jure-Kunkel

Yashwant M Deo

Subinay Ganguly

Laura J Hefta

Marc Santoro

Kent B Thudium

Arnout F Gerritsen

Jan G J Van De Winkel

Marcus A Van Dijk

Ole Baadsgaard

Heidi N Leblanc

Jennifer Marie Mataraza

Andrea Van Elsas

Timothy W Sproul

Mohan Srinivasan

David B Passmore

Jørgen Petersen

Jere E Meredith, Jr

Nino Devidze

Michael K Ahlijanian

John David Graef

Kent B Thuduim

Jan Van De Winkel

Changyu Wang

Kristopher Toy

Lan Yang

Willem Karel Bleeker

Jorgen Petersen

Marcus Antonius Van Dijk

Disclosed herein are anti-&#x3b1;-synuclein antibodies which preferentially bind to oligomeric &#x3b1;-synuclein over monomeric &#x3b1;-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.

Antibodies to alpha-synuclein and uses thereof

The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.

Fully human antibodies to BTLA

The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.

Transgenic transchromosomal rodents for making human antibodies

Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Human monoclonal antibodies to epidermal growth factor receptor (EGFR)

Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.

Fully human antibodies against human 4-1BB

Transgenic trasnchromosomal rodents for making human antibodies

The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.

Human CTLA-4 antibodies and their uses

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.

Human monoclonal antibodies to BTLA and methods of use

Growing community of inventors

Sunnyvale, CA, United States of America

Edward L Halk